The Nottingham and Nottinghamshire ICB ( Integrated Care Board ) reports that ongoing challenges, nationally and globally, with the supply of some Attention Deficit Hyperactivity Disorder (ADHD) medications are continuing.
A spokesperson said on 16 September:
‘This is causing some patients problems when accessing their regular treatment.
‘The availability of some of these medicines has been intermittent since Autumn 2023. While the overall position has improved, we have continued to experience shortages of different medicines at different times. Currently, our pharmacists are reporting shortages of brands of Methylphenidate.
‘We sympathise with all those ADHD patients who continue to have difficulty accessing their regular medication. These problems continue to be caused by a combination of manufacturing issues and a significant increase in demand across the world, not just in the UK. This is beyond our control.
‘ADHD patients and carers should continue to contact the NHS health care service they normally use if they require further support.
‘Locally and nationally, the NHS and its partners are making every effort to manage these supply problems and we appreciate your patience and understanding as we work with you to try to find the best solution which will be different for everyone.
‘Since last September, in Nottingham and Nottinghamshire, a taskforce made up of pharmacy, primary care, hospital and healthcare trust leads has been working together to mitigate these issues locally the best we possibly can. We are extremely grateful to everyone working in primary care and in local ADHD services for the help they continue to provide for patients and their families, particularly those requiring alternative treatments and additional support and advice.’
• Nottingham City Council accepts ‘backstop audit’ on 2019/20 accounts